BridgeMD
New treatment option for Iliotibial Band Syndrome
Official title Radial Extracorporeal Shockwave Therapy in Individuals With Iliotibial Band Syndrome
ClinicalTrials.gov ID: NCT07668011
What this study is testing
- What it's testing
- The goal of this Clinical Trial Study is to evaluate the clinical effectiveness of Radial Electrocorporeal Shockwave Therapy (rESWT) combined with exercise in individuals with iliotibial band syndrome (ITBS).The main question it aims to answer is : Does the addition of rESWT to standard ITBS exercise program reduce pain intensity and pain pressure threshold while improving lower extremity function and hip muscle strength in Individuals with Iliotibial Band syndrome (ITBS). Participants will be divided into two groups to be compared : The ShamTherapy Group (Control Group) that will receive the standard ITBS exercise program in addition to Sham rESWT, while the experimental group will receive the standard ITBS exercise program in addition to Radial Extracorporeal Shockwave Therapy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45
You may be able to join if
- Physically active individuals aged 18 and 45 years
- Have a clinical diagnosis of iliotibial band syndrome (ITBS) confirmed by physician within the previous four weeks.
- Report lateral knee pain during running or other functional activities
- No history of direct trauma
- Have a positive Noble compression or/and Ober test.
You likely can't join if
- History of knee surgery,fracture , meniscal or ligamentous injury within the past year
- Any fracture involving the lower extremity within the previous six months
- Neurological disorders
- Lumbar radiculopathy
- Systemic inflammatory disease
- Any medical condition affecting gat or lower extremity function.
See the full eligibility criteria
- Physically active individuals aged 18 and 45 years
- Have a clinical diagnosis of iliotibial band syndrome (ITBS) confirmed by physician within the previous four weeks.
- Report lateral knee pain during running or other functional activities
- No history of direct trauma
- Have a positive Noble compression or/and Ober test.
- History of knee surgery,fracture , meniscal or ligamentous injury within the past year
- Any fracture involving the lower extremity within the previous six months
- Neurological disorders
- Lumbar radiculopathy
- Systemic inflammatory disease
- Any medical condition affecting gat or lower extremity function.
- Have received corticosteroid injection, shockwave therapy, or physical therapy treatment for ITBS within the previous six months
- Use of NDAID's or analgesics later than 2 weeks
- Individuals with contraindications to ESWT, including pregnancy, bleeding disorders, or use of anticoagulant medication.
The study team makes the final eligibility decision.
Where it's taking place
- Giza, Giza Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Giza, Giza Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.